The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: The previous individual patient data meta-analyses of chemotherapy in locally advanced non–small-cell lung cancer (NSCLC) showed that adding sequential or concomitant chemotherapy to radiotherapy improved survival. The NSCLC Collaborative Group performed a meta-analysis of randomized trials directly comparing concomitant versus sequential radiochemotherapy. Methods: Systematic searches for trials were undertaken, followed by central collection, checking, and reanalysis of updated individual patient data. Results from trials were combined using the stratified log-rank test to calculate pooled hazard ratios (HRs). The primary outcome was overall survival; secondary outcomes were progression-free survival, cumulative incidences of locoregional and distant progression, and acute toxicity. Results: Of seven eligible trials, data from six trials were received (1,205 patients, 92% of all randomly assigned patients). Median follow-up was 6 years. There was a significant benefit of concomitant radiochemotherapy on overall survival (HR, 0.84; 95% CI, 0.74 to 0.95; P = .004), with an absolute benefit of 5.7% (from 18.1% to 23.8%) at 3 years and 4.5% at 5 years. For progression-free survival, the HR was 0.90 (95% CI, 0.79 to 1.01; P = .07). Concomitant treatment decreased locoregional progression (HR, 0.77; 95% CI, 0.62 to 0.95; P = .01); its effect was not different from that of sequential treatment on distant progression (HR, 1.04; 95% CI, 0.86 to 1.25; P = .69). Concomitant radiochemotherapy increased acute esophageal toxicity (grade 3-4) from 4% to 18% with a relative risk of 4.9 (95% CI, 3.1 to 7.8; P < .001). There was no significant difference regarding acute pulmonary toxicity. Conclusion: Concomitant radiochemotherapy, as compared with sequential radiochemotherapy, improved survival of patients with locally advanced NSCLC, primarily because of a better locoregional control, but at the cost of manageable increased acute esophageal toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,792
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Pignon, J.-P., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,069
Self-citationNon-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., & Ariyoshi, Y. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2692 · Cited by 1,495
Self-citation
Cited by
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Self-citationPostmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., Hui, R., Quantin, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01308 · Cited by 1,445
Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L., & Rosell, R. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.9 · Cited by 1,083
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Management of non-small-cell lung cancer: recent developments
Reck, M., Heigener, D. F., Mok, T., Soria, J.-C., & Rabe, K. F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61502-0 · Cited by 714
Goldstraw, P., Ball, D., Jett, J. R., Le Chevalier, T., Lim, E., Nicholson, A. G., & Shepherd, F. A. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62101-0 · Cited by 711
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Hanania, A. N., Mainwaring, W., Ghebre, Y. T., Hanania, N. A., & Ludwig, M. (2019) · Chest · doi:10.1016/j.chest.2019.03.033 · Cited by 638
Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M., Keijser, A., Faivre-Finn, C., & Senan, S. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61085-0 · Cited by 604
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Concurrent chemoradiotherapy in non-small cell lung cancer
O'Rourke, N., Roqué i Figuls, M., Farré Bernadó, N., & Macbeth, F. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002140.pub3 · Cited by 452
Senan, S., Brade, A., Wang, L.-H., Vansteenkiste, J., Dakhil, S., Biesma, B., Martinez Aguillo, M., Aerts, J., Govindan, R., Rubio-Viqueira, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8824 · Cited by 433
Prasad, V., Kim, C., Burotto, M., & Vandross, A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.2829 · Cited by 403
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
Eberhardt, W. E. E., De Ruysscher, D., Weder, W., Le Péchoux, C., De Leyn, P., Hoffmann, H., Westeel, V., Stahel, R., Felip, E., Peters, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv187 · Cited by 401
Self-citationInduction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Pless, M., Stupp, R., Ris, H.-B., Stahel, R. A., Weder, W., Thierstein, S., Gerard, M.-A., Xyrafas, A., Früh, M., Cathomas, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60294-x · Cited by 390
Eberhardt, W. E. E., Pöttgen, C., Gauler, T. C., Friedel, G., Veit, S., Heinrich, V., Welter, S., Budach, W., Spengler, W., Kimmich, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6812 · Cited by 365
De Ruysscher, D., Faivre-Finn, C., Nestle, U., Hurkmans, C. W., Le Péchoux, C., Price, A., & Senan, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3271 · Cited by 364
Self-citationDess, R. T., Sun, Y., Matuszak, M. M., Sun, G., Soni, P. D., Bazzi, L., Murthy, V. L., Hearn, J. W. D., Kong, F.-M., Kalemkerian, G. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6142 · Cited by 362
MR-guidance in clinical reality: current treatment challenges and future perspectives
Corradini, S., Alongi, F., Andratschke, N., Belka, C., Boldrini, L., Cellini, F., Debus, J., Guckenberger, M., Hörner-Rieber, J., Lagerwaard, F. J., et al. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1308-y · Cited by 356
Antitumor effectiveness of electrochemotherapy: A systematic review and meta-analysis
Mali, B., Jarm, T., Snoj, M., Sersa, G., & Miklavcic, D. (2013) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2012.08.016 · Cited by 353
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
Lu, S., Kato, T., Dong, X., Ahn, M.-J., Quang, L.-V., Soparattanapaisarn, N., Inoue, T., Wang, C.-L., Huang, M., Yang, J. C.-H., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402614 · Cited by 346
Gong, X., Li, X., Jiang, T., Xie, H., Zhu, Z., Zhou, F., & Zhou, C. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.014 · Cited by 303
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
Daly, M. E., Singh, N., Ismaila, N., Antonoff, M. B., Arenberg, D. A., Bradley, J., David, E., Detterbeck, F., Früh, M., Gubens, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02528 · Cited by 283
Speirs, C. K., DeWees, T. A., Rehman, S., Molotievschi, A., Velez, M. A., Mullen, D., Fergus, S., Trovo, M., Bradley, J. D., & Robinson, C. G. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.134 · Cited by 282
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non–Small Cell Lung Cancer
Ko, E. C., Raben, D., & Formenti, S. C. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3620 · Cited by 278
Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome
Salem, A., Asselin, M.-C., Reymen, B., Jackson, A., Lambin, P., West, C. M. L., O’Connor, J. P. B., & Faivre-Finn, C. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx160 · Cited by 266
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 259
Jabbour, S. K., Berman, A. T., Decker, R. H., Lin, Y., Feigenberg, S. J., Gettinger, S. N., Aggarwal, C., Langer, C. J., Simone, C. B., Bradley, J. D., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6731 · Cited by 125
Rios Velazquez, E., Aerts, H. J. W. L., Gu, Y., Goldgof, D. B., De Ruysscher, D., Dekker, A., Korn, R., Gillies, R. J., & Lambin, P. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.09.023 · Cited by 120
“About 80% of the lung cancer patients present advanced-stage disease (stages III and IV) and are considered inoperable due to loco-regional tumor extension, extra thoracic spread or poor physical condition at the time of diagnosis [2].”
BackgroundPET in the management of locally advanced and metastatic NSCLC
Grootjans, W., de Geus-Oei, L.-F., Troost, E. G. C., Visser, E. P., Oyen, W. J. G., & Bussink, J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.75 · Cited by 97
Wang, Y., Hu, G.-F., & Wang, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136259 · Cited by 21
“…T cells more sensitive to apoptosis, and promote the differentiation of naive T cells into regulatory T cells (Tregs) that can directly inhibit the host immune response, 18,20,27,40–42 and 3) secreting immunosuppressive cytokines, such as IL-10 and TGF-β , to protect tumor form host immunity.”
Lung Cancer Management in Low and Middle-Income Countries
Jiwnani, S., Penumadu, P., Ashok, A., & Pramesh, C. S. (2022) · Thoracic Surgery Clinics · doi:10.1016/j.thorsurg.2022.04.005 · Cited by 19
Metadata
- Authors
- Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., Yamanaka, T., Bozonnat, M.-C., Uitterhoeve, A., Wang, X., Stewart, L., Arriagada, R., Burdett, S., & Pignon, J.-P.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-05-01
- Volume
- 28
- Issue
- 13
- Pages
- 2181-2190
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2104701073
- Cited by
- 1,878
- References
- 27
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.